Source link : https://newshealth.biz/health-news/olpasiran-benefit-beyond-blocking-lpa/
An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 trial that its use can also lead to a significant and sustained reduction in oxidized phospholipids, according to new data. A phase 3 outcomes trial for olpasiran […]
The post Olpasiran Benefit Beyond Blocking Lp(a) first appeared on News Health.
Author : News Health
Publish date : 2025-03-13 10:35:00
Copyright for syndicated content belongs to the linked Source.